Caifeng Gong

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, National Cancer Center · ORCID：0000-0002-1864-8206

发表论文 53 篇 · 总被引 271 次 · h-index 8

代表论文

• Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer (2025 · Human Vaccines & Immunotherapeutics · 被引 8)
• Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study (2024 · Journal of Thoracic Oncology · 被引 7)
• Abnormal generation of IL-17A represses tumor infiltration of stem-like exhausted CD8+ T cells to demote the antitumor immunity (2023 · BMC Medicine · 被引 6)
• Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients (2023 · iScience · 被引 5)
• TPP1 is associated with risk of advanced precursors and cervical cancer survival (2024 · PLoS ONE · 被引 4)
• Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial (2025 · Cancer Immunology Immunotherapy · 被引 3)